Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The aim of the present study was to prepare and evaluate a rasagiline-loaded chitosan glutamate nanoparticles (RAS-CG-NPs) by ionic gelation of CG with tripolyphosphate anions (TPP). RAS-loaded CG-NPs were characterized for particle size, size distribution, encapsulation efficiency and in vitro drug release. The mean particles size, polydispersity index (PDI) and encapsulation efficiency was found to be 151.1 ± 10.31, 0.380 ± 0.01 and 96.43 ± 4.23, respectively. Biodistribution of RAS formulations in the brain and blood of mice following intranasal (i.n.) and intravenous (i.v.) administration was performed using HPLC analytical method. The drug concentrations in brain following the i.n. of CG-NPs were found to be significantly higher at all the time points compared to both drug (i.n.) and drug CG-NPs (i.v.). The Cmax (999.25 ng/ml) and AUC (2086.60 ng h/ml) of formulation CG-NPs (i.n) were found to be significantly higher than CG-NPs (i.v.) and RAS solution (i.n.). The direct transport percentage (DTP%) values of RAS-loaded CG-NPs (i.n.) as compared to drug solution (i.n.) increased from 66.27 ± 1.8 to 69.27 ± 2.1%. The results showed significant enhancement of bioavailability in brain, after administration of the RAS-loaded CG-NPs which could be a substantial achievement of direct nose to brain targeting in Parkinson's disease therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351 · cited 1×
“Parkinson’s disease (PD) is a progressive neurological disorder which affect around 2% of adults over the age of 60 years (Nussbaum & Ellis, 2003).”
BackgroundToxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251 · cited 1×
“The most consistent lesion in PD is degeneration of neurons in the substantia nigra pars compacta (SN-PC) (a region of the midbrain) and the nigrostriatal (dopaminergic) tract (Taylor et al., 2002).”
BackgroundIntranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239 · cited 2×
“The barriers are blood–brain barrier (BBB), blood cerebrospinal–fluid barrier (BCSFB) (Dhuria et al., 2010).”
BackgroundTransport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907 · cited 2×
“Nose-to-brain delivery of drug moieties have been attempted by several researchers to exploit the advantages of this route, such as circumvention of the BBB, avoidance of hepatic first-pass metabolism, practicality and convenience of administration and non-invasive nature (Illum, 2000).”
BackgroundIntranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435 · cited 3×
“), respectively, are indicative of the direct nose to brain transport bypassing the BBB, hence proving the superiority of nose to brain delivery of RAS by CG-NPs (Kumar et al., 2008).”
BackgroundMethodInfluentialInsights into Direct Nose to Brain Delivery: Current Status and Future Perspective
Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838713 · Cited by 359
Self-citationJoshi, S. A., Chavhan, S. S., & Sawant, K. K. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.07.007 · Cited by 235 · cited 2×
“Thus, diminished peak at about 180 C exhibited by RAS in the RAS-loaded NPs, indicating that small amount of drug adsorbed on the surface of nanoparticles and maximum was encapsulated by the polymer in the NPs (Joshi et al., 2010) and the characteristic peak of the drug has almost disappeared as it is anticipated that…”
Background
Cited by
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
“This study indicated the potential of chitosan NPs in the treatment of Parkinson's disease via direct intranasal brain targeting [182].”
BackgroundSurface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
“3 [100] Chitosan NPs Pramipexole PD 292.”
BackgroundNanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies
Pires, P. C., & Santos, A. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.047 · Cited by 228
Shah, B., Khunt, D., Misra, M., & Padh, H. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.076 · Cited by 112
Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review
Rassu, G., Soddu, E., Cossu, M., Gavini, E., Giunchedi, P., & Dalpiaz, A. (2016) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.05.002 · Cited by 87
Metadata
- Authors
- Mittal, D., Md, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., & Ali, J.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2014-04-30
- Volume
- 23
- Issue
- 1
- Pages
- 130-139
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W1974503082
- Cited by
- 117
- References
- 8
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. https://app.cochat.ai/papers/10.3109/10717544.2014.907372
- The paper
- Mittal, D., Md, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., & Ali, J. (2016). Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Delivery. https://doi.org/10.3109/10717544.2014.907372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.